1IA
AVDL

1620 Investment Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

1620 Investment Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-290
Closed -$6.25K – 663
2025
Q4 		$6.25K Hold
290
– – ﹤0.01% 501
2025
Q3 		$4.43K Hold
290
– – ﹤0.01% 526
2025
Q2 		$2.57K Sell
290
-710
-71% -$6.24K ﹤0.01% 584
2025
Q1 		$7.83K Hold
1,000
– – 0.01% 472
2024
Q4 		$10.5K Hold
1,000
– – 0.01% 449
2024
Q3 		$13.1K Hold
1,000
– – 0.01% 445
2024
Q2 		$14.1K Buy
+1,000
New +$16.3K 0.01% 430

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

1620 Investment Advisors's AVDL Position: Q1 2026 in Review

1620 Investment Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 290 shares — an estimated $6.25K sold.

1620 Investment Advisors first reported a position in AVDL in Q2 2024 and held it in 7 quarters. The position peaked at $14.1K in Q2 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • 1620 Investment Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • 1620 Investment Advisors sold 290 Avadel Pharmaceuticals shares in Q1 2026, an estimated $6.25K.
  • 1620 Investment Advisors first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 7 quarters.
  • 1620 Investment Advisors's Avadel Pharmaceuticals position peaked at $14.1K in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on 1620 Investment Advisors's 13F filing for Q1 2026, filed 13 May 2026.